Navigation Links
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Date:11/29/2007

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-generation drug eluting stent intended for use in the treatment of coronary artery disease.

The FDA advisory committee voted to recommend the XIENCE V stent system for approval with conditions related to post-marketing study requirements and language related to dual antiplatelet therapy. The FDA is not required to, but usually follows the recommendations of its advisory committees.

"The clinical and angiographic benefits of the XIENCE V stent compared to the most widely used drug eluting stent available in the U.S. have been consistent and significant across the SPIRIT trials," said Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation, New York and principal investigator of the SPIRIT III clinical trial. "The robust body of safety and efficacy data support approval of XIENCE V as an important new technology that will enhance the lives of millions of patients with heart disease."

Abbott filed its Premarket Approval (PMA) submission for XIENCE V with the FDA on June 1, 2007. The PMA for XIENCE V is the first to include data demonstrating superiority of one drug eluting stent over another in the primary endpoint of in-segment late loss in a randomized controlled head-to-head trial with a market leading product.

"The outcome of today's advisory committee meeting is very encouraging," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We look forward to bringing this important new treatment for coronary artery disease to physicians and patients in the U.S."

XIENCE V was launched in Europe and other international markets in 2006. XIENCE V is currently an investigational device in the United States and Japan.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com


'/>"/>
SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced expansion into Canada to provide its range of unique and advantaged ... in Quebec City that will provide bilingual customer service and marketing support. A ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Delta Dental ... to help combat pancreatic cancer. , Gary D. Radine, who recently retired as president ... the American Cancer Society’s 2015 CEO of the Year , helped lead the ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... variety of organizations. DocuSyst provides a cloud hosted environment for FileHold software ... include integration with various 3rd party applications using the FileHold web services API. ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... (NADL), only four states in the U.S. require dental technicians to be certified ... in the dental industry, NADL created the “What’s In Your Mouth?” campaign to ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Echo Therapeutics, Inc. ... company focused on non-invasive continuous glucose monitoring ... announced that it will host a webcast ... 2015 at 9:00 a.m. Eastern Time to ... corporate strategy, advancements in its CGM system, ...
(Date:2/8/2016)... historic vote among its members this weekend, the Shinnecock Indian Nation voted ... dispensary on tribal land near Southampton . ... patients in the state,s Medical Cannabis Program. --> ... the state,s Medical Cannabis Program. --> Tribal members voted ... from the State of New York as a ...
(Date:2/8/2016)... Switzerland and PALO ALTO, Calif. , Feb. ... and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical ... of retinal disease, announced today agreements for the clinical ... will manufacture material at multiple sites, including Slough (UK), ... --> --> Retinal diseases, such as ...
Breaking Medicine Technology: